JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Suletud

SektorTervishoid

14.85 1.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.27

Max

14.97

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+9.51% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.36%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	44M 295M
Eelmine avamishind	13.14
Eelmine sulgemishind	14.85

Uudiste sentiment

By Acuity

13%

87%

22 / 348 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. apr 2026, 23:33 UTC

Kuumad aktsiad

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28. apr 2026, 23:24 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28. apr 2026, 22:46 UTC

Tulu

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28. apr 2026, 22:37 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28. apr 2026, 22:15 UTC

Tulu

Uudisväärsed sündmused

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28. apr 2026, 23:19 UTC

Market Talk

Tulu

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28. apr 2026, 23:09 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28. apr 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees One Rate Rise to 4% in Benign Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28. apr 2026, 22:51 UTC

Tulu

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28. apr 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. apr 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28. apr 2026, 22:40 UTC

Market Talk

Uudisväärsed sündmused

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28. apr 2026, 22:32 UTC

Tulu

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28. apr 2026, 22:22 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28. apr 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28. apr 2026, 22:07 UTC

Market Talk

Uudisväärsed sündmused

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

9.51% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 9.51%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

22 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.